Key result
Etoposide plus cisplatin or carboplatin induces repeated tumor regression in a metastatic adamantinoma patient.
Why the study?
The biologic behavior and clinical course of metastatic adamantinoma of bone and its response to chemotherapy are not well characterized.
A combination chemotherapeutic regimen of etoposide plus cisplatin or carboplatin may induce tumor regression in patients with metastatic adamantinoma.
Hypothesis-generating for etoposide-platinum activity in metastatic adamantinoma; Level 5 evidence leaves efficacy unconfirmed.
A patient with metastatic adamantinoma from the tibia is described, in whom the biologic behavior of the tumor and the clinical course that evolved was typical. Tumor regression was observed on two separate occasions to a combination chemotherapeutic regimen of etoposide plus cisplatin or carboplatin.
No takes yet. Share an insight, caveat, or question.
Jacob J. Lokich (1994) studied this question. Combination chemotherapy with etoposide plus cisplatin or carboplatin induced tumor regression on two separate occasions in a patient with metastatic adamantinoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: